Measurement of the Electromechanical Window to Improve the Diagnosis of Congenital Long QT Syndrome (FEMQT)

February 21, 2022 updated by: University Hospital, Bordeaux
The goal of this research is to prospectively evaluate the performance of the electromechanical window according to a phonographic method, as a mean of diagnosis of long QT syndrome, and to compare its performance with routine tests used.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Familial long QT syndrome (LQTS) is a hereditary cardiac disorder in which most affected family members have delayed ventricular repolarization manifest on the electrocardiogram (ECG) as QT prolongation. This disease is associated with an increased propensity to palpitations, syncope, polymorphous ventricular tachycardia and sudden arrhythmic death. The diagnosis relies mostly on resting ECG findings and on genetic testing. In clinical practice however, this diagnosis is complicated by 2 main reasons: 1) a significant overlap in ECG findings between healthy and diseased individuals and 2) a frequent identification of genetic variants of unknown significance. Recent studies have suggested that echocardiographic measurement of the electromechanical window (EMW - the delay between the end of mechanical contraction and electrical activation of the heart) has better performance in the diagnosis of LQTS. The echocardiographic technique is however too complicated for routine clinical use. Preliminary work conducted at the University Hospital of Bordeaux and at the University Hospital of Reunion Island has demonstrated that a phonocardiographic approach leads to similar results with an improved feasibility and a good reproducibility.

Study Type

Interventional

Enrollment (Anticipated)

224

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Nantes, France, 44093
        • Not yet recruiting
        • Nantes University Hospital
        • Contact:
        • Principal Investigator:
          • Vincent PROBST, MD PhD
      • Pessac, France, 33604
        • Recruiting
        • Bordeaux University Hospital
        • Sub-Investigator:
          • Romain TIXIER, MD
        • Contact:
        • Principal Investigator:
          • Josselin DUCHATEAU, MD
        • Sub-Investigator:
          • Frédéric SACHER, MD, PhD
      • Saint-Pierre, France, 97410
        • Recruiting
        • La réunion university hospital
        • Contact:
        • Principal Investigator:
          • Maxime CHURET, MD
        • Sub-Investigator:
          • Olivier GEOFFROY, MD
      • Toulouse, France, 31400
        • Recruiting
        • Toulouse University Hospital
        • Contact:
        • Principal Investigator:
          • jean-Philippe MAURY, MD PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

10 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Propositus patients with genetically proven LQTS and their relatives,
  • Patients of both sexes aged 12 and over,
  • Free, informed and written consent of the patient and the two holders of parental authority for minors.

Exclusion Criteria:

  • Inability to consent,
  • Person deprived of liberty by judicial or administrative decision,
  • Majors subject to a legal protection measure,
  • Person participating in another research including an exclusion period still in progress,
  • Severely impaired physical and / or psychological health, which, according to the investigator, may affect the participant's compliance with the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Prospective FEMQT Group
Propositus patients with genetically proven LQTS and their relatives

A standard ECG is recorded along with a phonocardiographic recording. The phonocardiographic recording is obtained by using a specific electronic stethoscope plugged into the auxiliary port of the ECG machine. The recording takes less than 30 seconds. The two recording methods are concomitant.

QT interval is measured on the ECG recording, EMW is measured with ECG coupled to phonocardiography.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Negative predictive value (NPV) obtained by the two methods of diagnosis
Time Frame: Day 1
The NPV is measured in percentage. The NPV of LQTS diagnosis obtained by phonocardiographic method (measurement of the EMW) and the NPV obtained by standard ECG method (QT measurement prolongation) will be compared.
Day 1

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Values of sensitivity obtained by the two methods of diagnosis
Time Frame: Day 1
Value of sensitivity is measured in percentage. The values of sensitivity of EMW and standard ECG will be compared.
Day 1
Values of specificity obtained by the two methods of diagnosis
Time Frame: Day 1
Value of specificity is measured in percentage. The values of specificity of EMW and standard ECG will be compared.
Day 1
Positive predictive values obtained by the two methods of diagnosis
Time Frame: Day 1
Positive predictive value is measured in percentage. Positive predictive values of EMW and standard ECG will be compared.
Day 1
Area Under the Curves (AUC) obtained by the two methods of diagnosis
Time Frame: Day 1

The AUC obtained by Receiver Operating Characteristic (ROC) analyses is measured by a value between 0 and 1.

The AUC obtained by ROC of EMW and standard ECG will be compared.

Day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Josselin DUCHATEAU, MD, University Hospital, Bordeaux

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 28, 2020

Primary Completion (Anticipated)

August 28, 2023

Study Completion (Anticipated)

August 28, 2023

Study Registration Dates

First Submitted

March 27, 2020

First Submitted That Met QC Criteria

March 27, 2020

First Posted (Actual)

March 31, 2020

Study Record Updates

Last Update Posted (Actual)

February 22, 2022

Last Update Submitted That Met QC Criteria

February 21, 2022

Last Verified

February 1, 2022

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Long QT Syndrome

Clinical Trials on ECG coupled to phonocardiography

3
Subscribe